Skip to content

EFFICACY OF TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION COMBINED WITH GENERAL ANESTHESIA FOR POSTOPERATIVE ANALGESIA AND SEDATION IN LUNG CANCER PATIENTS UNDERGOING THORACOSCOPIC RADICAL RESECTION OF PULMONARY CARCINOMA: a prospective randomized double-blind controlled clinical trial

EFFICACY OF TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION COMBINED WITH GENERAL ANESTHESIA FOR POSTOPERATIVE ANALGESIA AND SEDATION IN LUNG CANCER PATIENTS UNDERGOING THORACOSCOPIC RADICAL RESECTION OF PULMONARY CARCINOMA: a prospective randomized double-blind controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016067
Enrollment
Unknown
Registered
2018-05-09
Start date
2018-05-10
Completion date
Unknown
Last updated
2018-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Group A:transcutaneous electrical acupoint stimulation(TEAS)
Group C:transcutaneous sham electrical acupoint stimulation(TEAS)

Sponsors

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Anesthesiology,Peking University Cancer Hospital & Institute, Beijing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Pulmonary masses were diagnosed by thoracic surgery, and 80 patients underwent thoracoscopic radical resection of lung cancer. They had no history of chronic pain, no severe hypertension, heart disease, diabetes mellitus, no alcohol abuse, no drugs, no diseases of the blood system, no history of chronic pain before operation, no complications such as heart disease, diabetes mellitus and so on. Normal liver and kidney function, education level above primary school, willing to accept PCIA and pain score.

Exclusion criteria

Exclusion criteria: (1) not willing to conduct electrical stimulation of acupoints in Jianyan; (2) patients with local skin infection at the meridians; (3) patients with upper limb or lower extremity nerve injuries; (4) patients who have participated in other clinical trials within nearly four weeks; (5) patients who have not been able to cooperate with patients who have completed the research project, including language difficulties; (6) With severe liver, kidney, brain and lung diseases before operation. (7) BMI was >30 kg/m2; (8) With history of drug abuse.

Design outcomes

Primary

MeasureTime frame
VAS;

Secondary

MeasureTime frame
BIS;OAAS score;analgesic dosage;the number of attempts;

Countries

China

Contacts

Public ContactJiheng Chen

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Anesthesiology,Peking University Cancer Hospital & Institute

2238165366@qq.com+86 13552694668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026